Antibodies against acute phase proteins and their functions in the pathogenesis of disease: A collective profile of 25 different antibodies

Autoimmunity Reviews

Volumn 10, Issue 12, 2011, Pages 779-789

  Lakota, Katja ^a   Zigon, Polona ^a   Mrak Poljsak, Katjusa ^a   Rozman, Blaz ^a   Shoenfeld, Yehuda ^c   Sodin Semrl, Snezna ^a,b  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF PRIMORSKA   (Slovenia)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Acute phase proteins; Autoantibodies against acute phase proteins; Protective deleterious functions

Indexed keywords

ACUTE PHASE PROTEIN; ACUTE PHASE PROTEIN ANTIBODY; ALBUMIN ANTIBODY; ALPHA 1 ANTITRYPSIN ANTIBODY; ALPHA2 HEREMANS SCHMIDT GLYCOPROTEIN ANTIBODY; APOLIPOPROTEIN A1 ANTIBODY; APROTININ ANTIBODY; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; BLOOD CLOTTING FACTOR 12 ANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; C REACTIVE PROTEIN ANTIBODY; CERULOPLASMIN ANTIBODY; EPITOPE; FERRITIN ANTIBODY; FIBRINOGEN ANTIBODY; FIBRONECTIN ANTIBODY; HAPTOGLOBIN ANTIBODY; LIPOPROTEIN A ANTIBODY; MANGANESE SUPEROXIDE DISMUTASE ANTIBODY; MANNOSE BINDING LECTIN ANTIBODY; NEPHRITIC FACTOR ANTIBODY; PLASMINOGEN ANTIBODY; PROTEIN ANTIBODY; PROTEIN C ANTIBODY; PROTEIN S ANTIBODY; SERUM AMYLOID A ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR ANTIBODY; UNCLASSIFIED DRUG; ZINC ALPHA 2 GLYCOPROTEIN ANTIBODY;

ANGIONEUROTIC EDEMA; ANTIBODY SPECIFICITY; ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOVASCULAR DISEASE; COMPLEMENT SYSTEM; ENDOMETRIOSIS; FIBRINOLYSIS; GLOMERULONEPHRITIS; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INFECTION; INFLAMMATION; INJURY; INNATE IMMUNITY; NEOPLASM; OXIDATIVE STRESS; PANCREATITIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VASCULITIS;

ACUTE-PHASE PROTEINS; ATHEROSCLEROSIS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; HUMANS; INFLAMMATION; NEOPLASMS;

EID: 80053283485     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.06.001     Document Type: Review

References (132)

1. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999, 340:448-454.
2. Kravitz M.S., Pitashny M., Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 2005, 25:582-591.
3. Bell S.A., Faust H., Schmid A., Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 1998, 113:327-332.
4. Poletaev A., Osipenko L. General network of natural autoantibodies as immunological homunculus. Autoimmun Rev 2003, 2:264-271.
5. Tsonis I.A., Avrameas S., Moutsopoulos H.M. Autoimmunity and pathophysiology. J Autoimmun 2007, 29:203-205.
6. Lutz H.U., Binder C.J., Kaveri S. Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol 2009, 30:43-51.
7. Kravitz M.S., Shoenfeld Y. Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases?. Nat Clin Pract Rheumatol 2006, 2:481-490.
8. Shoenfeld Y., Szyper-Kravitz M., Witte T., Doria A., Tsutsumi A., Tatsuya A., et al. Autoantibodies against protective molecules-C1q, C-reactive protein, serum amyloid P, mannose-binding lectin, and apolipoprotein A1: prevalence in systemic lupus erythematosus. Ann N Y Acad Sci 2007, 1108:227-239.
9. Tan H.T., Low J., Lim S.G., Chung M.C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009, 276:6880-6904.
10. Boes M., Prodeus A.P., Schmidt T., Carroll M.C., Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med 1998, 188:2381-2386.
11. Lutz H.U. Homeostatic roles of naturally occurring antibodies: an overview. J Autoimmun 2007, 29:287-294.
12. Lakota K., Thallinger G.G., Cucnik S., Bozic B., Mrak-Poljsak K., Ambrozic A., et al. Could antibodies against serum amyloid A function as physiological regulators in humans?. Autoimmunity 2011, 44:149-158.
13. Algiman M., Dietrich G., Nydegger U.E., Boieldieu D., Sultan Y., Kazatchkine M.D. Natural antibodies to factor VIII (anti-hemophilic factor) in healthy individuals. Proc Natl Acad Sci USA 1992, 89:3795-3799.
14. Szabo P., Relkin N., Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun Rev 2008, 7:415-420.
15. Lakota K., Frank M., Buzan O., Tomsic M., Rozman B., Sodin-Semrl S. Acute phase proteins and their role in rheumatic inflammatory diseases: emphasis on serum amyloid A. Acute Phase Protein/Book 1, InTech, Rijeka 2011, pp. V. Francisco (Ed.).
16. Vollmers H.P., Brandlein S. Natural antibodies and cancer. J Autoimmun 2007, 29:295-302.
17. Horn M.P., Pachlopnik J.M., Vogel M., Dahinden M., Wurm F., Stadler B.M., et al. Conditional autoimmunity mediated by human natural anti-Fc(epsilon)RIalpha autoantibodies?. FASEB J 2001, 15:2268-2274.
18. Wootla B., Dasgupta S., Dimitrov J.D., Bayry J., Levesque H., Borg J.Y., et al. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. J Immunol 2008, 180:7714-7720.
19. Lacroix-Desmazes S., Bayry J., Kaveri S.V., Hayon-Sonsino D., Thorenoor N., Charpentier J., et al. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc Natl Acad Sci USA 2005, 102:4109-4113.
20. Galli M., Luciani D., Bertolini G., Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003, 102:2717-2723.
21. Bassi N., Ghirardello A., Blank M., Zampieri S., Sarzi-Puttini P., Mantovani A., et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis 2010, 69:1704-1710.
22. Gorgani N.N., Theofilopoulos A.N. Contribution of histidine-rich glycoprotein in clearance of immune complexes and apoptotic cells: implications for ameliorating autoimmune diseases. Autoimmunity 2007, 40:260-266.
23. Du Clos T.W. Function of C-reactive protein. Ann Med 2000, 32:274-278.
24. Sjöwall C., Bengtsson A.A., Sturfelt G., Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004, 6:R87-R94.
25. Wettero J., Nilsson L., Jonasson L., Sjowall C. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta 2009, 400:128-131.
26. Bell S.A., Du Clos T.W., Khursigara G., Picazo J.J., Rubin R.L. Autoantibodies to cryptic epitopes of C-reactive protein and other acute phase proteins in the toxic oil syndrome. J Autoimmun 1995, 8:293-303.
27. Sjowall C., Eriksson P., Almer S., Skogh T. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 2002, 19:155-160.
28. Rosenau B.J., Schur P.H. Antibodies to C reactive protein. Ann Rheum Dis 2006, 65:674-676.
29. Tan Y., Yu F., Yang H., Chen M., Fang Q., Zhao M.H. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol 2008, 69:840-844.
30. Sjowall C., Zickert A., Skogh T., Wettero J., Gunnarsson I. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther 2009, 11:R188.
31. Figueredo M.A., Rodriguez A., Ruiz-Yague M., Romero M., Fernandez-Cruz A., Gomez-de la Concha E., et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 2006, 33:1980-1986.
32. Tan Y., Yu F., Qu Z., Su T., Xing G.Q., Wu L.H., et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol 2011, 6:93-100.
33. Lakota K., Mrak-Poljsak K., Rozman B., Sodin-Semrl S. Serum amyloid A and its potential physiological/pathological functions - an overview of patents. Recent Pat Endocr Metab Immune Drug Disco 2010, 4:89-99.
34. Cabana V.G., Feng N., Reardon C.A., Lukens J., Webb N.R., de Beer F.C., et al. Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res 2004, 45:317-325.
35. Hirakura Y., Carreras I., Sipe J.D., Kagan B.L. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid 2002, 9:13-23.
36. Lavie M., Voisset C., Vu-Dac N., Zurawski V., Duverlie G., Wychowski C., et al. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology 2006, 44:1626-1634.
37. Rosenau B.J., Schur P.H. Antibody to serum amyloid A. J Autoimmun 2004, 23:179-182.
38. Jue D.M., Shim B.S., Kang Y.S. Inhibition of prostaglandin synthase activity of sheep seminal vesicular gland by human serum haptoglobin. Mol Cell Biochem 1983, 51:141-147.
39. Arredouani M., Matthijs P., Van Hoeyveld E., Kasran A., Baumann H., Ceuppens J.L., et al. Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology 2003, 108:144-151.
40. Koda Y., Watanabe Y., Soejima M., Shimada E., Nishimura M., Morishita K., et al. Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood 2000, 95:1138-1143.
41. Nishiki S., Hino M., Kumura T., Hashimoto S., Ohta K., Yamane T., et al. Effectiveness of washed platelet concentrate and red cell transfusions for a patient with anhaptoglobinemia with antihaptoglobin antibody. Transfus Med 2002, 12:71-73.
42. Harrison P.M., Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996, 1275:161-203.
43. Mewar D., Moore D.J., Young-Min S., Bertolaccini M.L., Khamashta M.A., Watson P.F., et al. Antiferritin antibodies discovered by phage display expression cloning are associated with radiographic damage in rheumatoid arthritis. Arthritis Rheum 2005, 52:3868-3872.
44. Ohno O., Tateishi H., Cooke T.D. Pathogenesis of chronic inflammation in experimental ferritin-induced arthritis. IV. Immuno-electron microscopic techniques in the study of articular collagenous tissues. Arthritis Rheum 1978, 21:81-91.
45. Biemond P., Swaak A.J., van Eijk H.G., Koster J.F. Intraarticular ferritin-bound iron in rheumatoid arthritis. A factor that increases oxygen free radical-induced tissue destruction. Arthritis Rheum 1986, 29:1187-1193.
46. Semrau F., Kuhl R.J., Ritter S., Ritter K. Manganese superoxide dismutase (MnSOD) and autoantibodies against MnSOD in acute viral infections. J Med Virol 1998, 55:161-167.
47. Dalpke A.H., Thomssen R., Ritter K. Oxidative injury to endothelial cells due to Epstein-Barr virus-induced autoantibodies against manganese superoxide dismutase. J Med Virol 2003, 71:408-416.
48. Eiffert H., Karsten A., Ritter K., Ohlenbusch A., Schlott T., Laskawi R., et al. Autoantibodies to human manganese superoxide dismutase (MnSOD) in children with facial palsy due to neuroborreliosis. Neuropediatrics 2005, 36:386-388.
49. Yang F., Xiao Z.Q., Zhang X.Z., Li C., Zhang P.F., Li M.Y., et al. Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res 2007, 6:751-758.
50. Umahara T., Uchihara T., Yamada S., Hashimoto T., Akimoto J., Haraoka J., et al. Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques. Atherosclerosis 2011, 215:392-398.
51. Etingin O.R., Hajjar D.P., Hajjar K.A., Harpel P.C., Nachman R.L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem 1991, 266:2459-2465.
52. Ichikawa T., Unoki H., Sun H., Shimoyamada H., Marcovina S., Shikama H., et al. Lipoprotein(a) promotes smooth muscle cell proliferation and dedifferentiation in atherosclerotic lesions of human apo(a) transgenic rabbits. Am J Pathol 2002, 160:227-236.
53. Romero F.I., Atsumi T., Tinahones F.J., Gomez-Zumaquero J.M., Amengual O., Khamashta M.A., et al. Autoantibodies against malondialdehyde-modified lipoprotein(a) in antiphospholipid syndrome. Arthritis Rheum 1999, 42:2606-2611.
54. Halme L., von Smitten K., Stenman S., Turpeinen U., Stenman U.H. Concentrations of pancreatic secretory trypsin inhibitor (PSTI), acute phase proteins, and neopterin in Crohn's disease. Comparison with clinical disease activity and endoscopical findings. Scand J Clin Lab Invest 1993, 53:359-366.
55. Asada M., Nishio A., Uchida K., Kido M., Ueno S., Uza N., et al. Identification of a novel autoantibody against pancreatic secretory trypsin inhibitor in patients with autoimmune pancreatitis. Pancreas 2006, 33:20-26.
56. Lohr J.M., Faissner R., Koczan D., Bewerunge P., Bassi C., Brors B., et al. Autoantibodies against the exocrine pancreas in autoimmune pancreatitis: gene and protein expression profiling and immunoassays identify pancreatic enzymes as a major target of the inflammatory process. Am J Gastroenterol 2010, 105:2060-2071.
57. Sarma J.V., Ward P.A. The complement system. Cell Tissue Res 2011, 343:227-235.
58. Gupta B., Raghav S.K., Agrawal C., Chaturvedi V.P., Das R.H., Das H.R. Anti-MBL autoantibodies in patients with rheumatoid arthritis: prevalence and clinical significance. J Autoimmun 2006, 27:125-133.
59. Mok M.Y., Jack D.L., Lau C.S., Fong D.Y., Turner M.W., Isenberg D.A., et al. Antibodies to mannose binding lectin in patients with systemic lupus erythematosus. Lupus 2004, 13:522-528.
60. Takahashi R., Tsutsumi A., Ohtani K., Goto D., Matsumoto I., Ito S., et al. Anti-mannose binding lectin antibodies in sera of Japanese patients with systemic lupus erythematosus. Clin Exp Immunol 2004, 136:585-590.
61. Seelen M.A., Trouw L.A., van der Hoorn J.W., Fallaux-van den Houten F.C., Huizinga T.W., Daha M.R., et al. Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. Clin Exp Immunol 2003, 134:335-343.
62. Schmaier A.H., Thornburg C.D., Pipe S.W. Coagulation and Fibrinolysis. Henry's Clinical Diagnosis and Management by Laboratory Methods 2007, 729-746. Elsevier, Philadelphia. R.A. McPherson, M.R. Pincus (Eds.).
63. Plow E.F., Edgington T.S. Immune responses to the cleavage-associated neoantigens of fibrinogen in man. Identification and characterization of humoral antibodies specific for cleavage fragments. J Clin Invest 1975, 56:1509-1518.
64. Kondera-Anasz Z. Antibodies against fibrinogen in pregnant women, in post delivery women and in the newborns. Thromb Haemost 1998, 79:963-968.
65. Hill J.A., Al-Bishri J., Gladman D.D., Cairns E., Bell D.A. Serum autoantibodies that bind citrullinated fibrinogen are frequently found in patients with rheumatoid arthritis. J Rheumatol 2006, 33:2115-2119.
66. Nielen M.M., van der Horst A.R., van Schaardenburg D., van der Horst-Bruinsma I.E., van de Stadt R.J., Aarden L., et al. Antibodies to citrullinated human fibrinogen (ACF) have diagnostic and prognostic value in early arthritis. Ann Rheum Dis 2005, 64:1199-1204.
67. Atta M.S., Lim K.L., Ala'deen D.A., Powell R.J., Todd I. Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus. Ann Rheum Dis 1995, 54:117-124.
68. Feist E., Hiepe F. Fibronectin autoantibodies. Autoantibodies 2007, 325-329. Elsevier, London. Y. Shoenfeld, M.E. Gershwin, P.L. Meroni (Eds.).
69. Duner P., To F., Alm R., Goncalves I., Fredrikson G.N., Hedblad B., et al. Immune responses against fibronectin modified by lipoprotein oxidation and their association with cardiovascular disease. J Intern Med 2009, 265:593-603.
70. Maehnss K., Kobarg J., Schmitt W.H., Hansen H.P., Lange H., Csernok E., et al. Vitronectin- and fibronectin-containing immune complexes in primary systemic vasculitis. J Autoimmun 2002, 18:239-250.
71. Bayry J., Lacroix-Desmazes S., Pashov A., Stahl D., Hoebeke J., Kazatchkine M.D., et al. Autoantibodies to factor VIII with catalytic activity. Autoimmun Rev 2003, 2:30-35.
72. Lacroix-Desmazes S., Misra N., Bayry J., Mohanty D., Kaveri S.V., Kazatchkine M.D. Autoantibodies to factor VIII. Autoimmun Rev 2002, 1:105-110.
73. Bautz D.J., Preston G.A., Lionaki S., Hewins P., Wolberg A.S., Yang J.J., et al. Antibodies with dual reactivity to plasminogen and complementary PR3 in PR3-ANCA vasculitis. J Am Soc Nephrol 2008, 19:2421-2429.
74. Bu C., Li Z., Zhang C., Gao L., Cai G. IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis. Clin Rheumatol 2008, 27:171-178.
75. Bu C., Zhang C., Li Z., Gao L., Xie Z., Cai G. Autoantibodies to plasminogen and tissue plasminogen activator in women with recurrent pregnancy loss. Clin Exp Immunol 2007, 149:31-39.
76. Banks R.E., Forbes M.A., Storr M., Higginson J., Thompson D., Raynes J., et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995, 102:217-223.
77. Adinolfi M., Lehner T. C9 and factor B as acute phase proteins and their diagnostic and prognostic value in disease. Exp Clin Immunogenet 1988, 5:123-132.
78. Bene L., Fust G., Fekete B., Kovacs A., Horvath L., Prohaszka Z., et al. High normal serum levels of C3 and C1 inhibitor, two acute-phase proteins belonging to the complement system, occur more frequently in patients with Crohn's disease than ulcerative colitis. Dig Dis Sci 2003, 48:1186-1192.
79. Meszaros T., Fust G., Farkas H., Jakab L., Temesszentandrasi G., Nagy G., et al. C1-inhibitor autoantibodies in SLE. Lupus 2010, 19:634-638.
80. Spitzer R.E., Stitzel A.E., Tsokos G. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production. Clin Immunol Immunopathol 1992, 64:177-183.
81. Tsokos G.C., Shoenfeld Y., Gershwin M.E., Meroni P.L. Nephritic factor autoantibodies. Autoantibodies 2007, 561-566. Elsevier, London.
82. Strobel S., Zimmering M., Papp K., Prechl J., Jozsi M. Anti-factor B autoantibody in dense deposit disease. Mol Immunol 2010, 47:1476-1483.
83. Sakai M., Asayama K., Otabe T., Kohri T., Shirahata A. Low tissue plasminogen activator relative to plasminogen activator inhibitor-1 as a marker of cardiac complication in children with Kawasaki disease. Clin Appl Thromb Hemost 2001, 7:214-218.
84. Cugno M., Castelli R., Bisiani G., Griffini S., Meroni P.L. Anti-t-PA antibodies in acute myocardial infarction after thrombolysis with rt-PA. Eur J Intern Med 2010, 21:25-29.
85. Saibeni S., Ciscato C., Vecchi M., Boscolo Anzoletti M., Kaczmarek E., Caccia S., et al. Antibodies to tissue-type plasminogen activator (t-PA) in patients with inflammatory bowel disease: high prevalence, interactions with functional domains of t-PA and possible implications in thrombosis. J Thromb Haemost 2006, 4:1510-1516.
86. Lu C.S., Horizon A.A., Hwang K.K., FitzGerald J., Lin W.S., Hahn B.H., et al. Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome. Arthritis Rheum 2005, 52:4018-4027.
87. Pang W.W., Abdul-Rahman P.S., Wan-Ibrahim W.I., Hashim O.H. Can the acute-phase reactant proteins be used as cancer biomarkers?. Int J Biol Markers 2010, 25:1-11.
88. Albertus D.L., Seder C.W., Chen G., Wang X., Hartojo W., Lin L., et al. AZGP1 autoantibody predicts survival and histone deacetylase inhibitors increase expression in lung adenocarcinoma. J Thorac Oncol 2008, 3:1236-1244.
89. McPherson R.A. Specific proteins. Henry's Clinical Diagnosis and Management by Laboratory Methods 2007, 231-244. Elsevier, Philadelphia. R.A. McPherson, M.R. Pincus (Eds.).
90. Sansonno D.E., Detomaso P., Papanice M.A., Primavera M.V., Manghisi O.G. Autoantibody to albumin of type G and M in acute and chronic viral hepatitis. Hepatogastroenterology 1986, 33:14-16.
91. Rasheed Z., Khan M.W., Ali R. Hydroxyl radical modification of human serum albumin generated cross reactive antibodies. Autoimmunity 2006, 39:479-488.
92. Sheikh Z., Ahmad R., Sheikh N., Ali R. Enhanced recognition of reactive oxygen species damaged human serum albumin by circulating systemic lupus erythematosus autoantibodies. Autoimmunity 2007, 40:512-520.
93. Khan M.W., Qadrie Z.L., Khan W.A. Antibodies against gluco-oxidatively modified human serum albumin detected in diabetes-associated complications. Int Arch Allergy Immunol 2010, 153:207-214.
94. Vuilleumier N., Reber G., James R., Burger D., de Moerloose P., Dayer J.M., et al. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 2004, 23:353-360.
95. Abe H., Tsuboi N., Suzuki S., Sakuraba H., Takanashi H., Tahara K., et al. Anti-apolipoprotein A-I autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus erythematosus. J Rheumatol 2001, 28:990-995.
96. Marcel Y.L., Jewer D., Leblond L., Weech P.K., Milne R.W. Lipid peroxidation changes the expression of specific epitopes of apolipoprotein A-I. J Biol Chem 1989, 264:19942-19950.
97. Dinu A.R., Merrill J.T., Shen C., Antonov I.V., Myones B.L., Lahita R.G. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 1998, 7:355-360.
98. Delgado Alves J., Kumar S., Isenberg D.A. Cross-reactivity between anti-cardiolipin, anti-high-density lipoprotein and anti-apolipoprotein A-I IgG antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2003, 42:893-899.
99. O'Neill S.G., Giles I., Lambrianides A., Manson J., D'Cruz D., Schrieber L., et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010, 62:845-854.
100. Batuca J.R., Ames P.R., Amaral M., Favas C., Isenberg D.A., Delgado Alves J. Anti-atherogenic and anti-inflammatory properties of high-density lipoprotein are affected by specific antibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2009, 48:26-31.
101. Vuilleumier N., Bas S., Pagano S., Montecucco F., Guerne P.A., Finckh A., et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:2640-2650.
102. Domingo N., Grosclaude J., Bekaert E.D., Mege D., Chapman M.J., Shimizu S., et al. Epitope mapping of the human biliary amphipathic, anionic polypeptide: similarity with a calcium-binding protein isolated from gallstones and bile, and immunologic cross-reactivity with apolipoprotein A-I. J Lipid Res 1992, 33:1419-1430.
103. Lebreton J.P., Joisel F., Raoult J.P., Lannuzel B., Rogez J.P., Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979, 64:1118-1129.
104. Pillai S., Zhou G.X., Arnaud P., Jiang H., Butler W.J., Zhang H. Antibodies to endometrial transferrin and alpha 2-Heremans Schmidt (HS) glycoprotein in patients with endometriosis. Am J Reprod Immunol 1996, 35:483-494.
105. Yi J.K., Chang J.W., Han W., Lee J.W., Ko E., Kim D.H., et al. Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis. Cancer Epidemiol Biomarkers Prev 2009, 18:1357-1364.
106. Wang K., Xu X., Nie Y., Dai L., Wang P., Zhang J. Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma. Cancer Lett 2009, 281:144-150.
107. Brighton T.A., Hogg P.J., Dai Y.P., Murray B.H., Chong B.H., Chesterman C.N. Beta 2-glycoprotein I in thrombosis: evidence for a role as a natural anticoagulant. Br J Haematol 1996, 93:185-194.
108. Sodin-Semrl S., Rozman B. Beta2-glycoprotein I and its clinical significance: from gene sequence to protein levels. Autoimmun Rev 2007, 6:547-552.
109. Marai I., Tincani A., Balestrieri G., Shoenfeld Y. Anticardiolipin and anti-beta-2-glycoprotein I antibodies. Autoimmunity 2005, 38:33-38.
110. de Laat B., Mertens K., de Groot P.G. Mechanisms of disease: antiphospholipid antibodies-from clinical association to pathologic mechanism. Nat Clin Pract Rheumatol 2008, 4:192-199.
111. Cucnik S., Bozic B., Kveder T., Tomsic M., Rozman B. Avidity of anti-beta2-glycoprotein I and thrombosis or pregnancy loss in patients with antiphospholipid syndrome. Ann N Y Acad Sci 2005, 1051:141-147.
112. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
113. Citarella F., Felici A., Brouwer M., Wagstaff J., Fantoni A., Hack C.E. Interleukin-6 downregulates factor XII production by human hepatoma cell line (HepG2). Blood 1997, 90:1501-1507.
114. Jones D.W., MacKie I.J., Gallimore M.J., Winter M. Antibodies to factor XII and recurrent fetal loss in patients with the anti-phospholipid syndrome. Br J Haematol 2001, 113:550-552.
115. Inomo A., Sugi T., Fujita Y., Matsubayashi H., Izumi S., Mikami M. The antigenic binding sites of autoantibodies to factor XII in patients with recurrent pregnancy losses. Thromb Haemost 2008, 99:316-323.
116. Bertolaccini M.L., Mepani K., Sanna G., Hughes G.R., Khamashta M.A. Factor XII autoantibodies as a novel marker for thrombosis and adverse obstetric history in patients with systemic lupus erythematosus. Ann Rheum Dis 2007, 66:533-536.
117. Jones D.W., Gallimore M.J., MacKie I.J., Harris S.L., Winter M. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol 2000, 110:721-726.
118. Macko R.F., Ameriso S.F., Gruber A., Griffin J.H., Fernandez J.A., Barndt R., et al. Impairments of the protein C system and fibrinolysis in infection-associated stroke. Stroke 1996, 27:2005-2011.
119. Sorice M., Arcieri P., Griggi T., Circella A., Misasi R., Lenti L., et al. Inhibition of protein S by autoantibodies in patients with acquired protein S deficiency. Thromb Haemost 1996, 75:555-559.
120. Guermazi S., Regnault V., Gorgi Y., Ayed K., Lecompte T., Dellagi K. Further evidence for the presence of anti-protein S autoantibodies in patients with systemic lupus erythematosus. Blood Coagul Fibrinolysis 2000, 11:491-498.
121. Morange P.E., Alessi M.C., Barthet M.C., Aillaud M.F., Harle J.R., Piquet P., et al. Acquired protein S deficiency, likely due to anti-PS autoantibodies, following a thrombotic event in a patient with a systemic lupus erythematosus. Thromb Haemost 1997, 78:1416-1417.
122. Song K.S., Park Y.S., Kim H.K. Prevalence of anti-protein S antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 2000, 43:557-560.
123. Kasuno K., Tsuzuki D., Tanaka A., Ueda S., Sugawara A., Senzaki H., et al. A 41-year-old woman with protein S deficiency and diffuse proliferative lupus nephritis: is protein S deficiency associated with a hyperinflammatory response?. Am J Kidney Dis 1997, 29:931-935.
124. Erkan D., Zhang H.W., Shriky R.C., Merrill J.T. Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus 2002, 11:215-220.
125. Bergmann F., Hoyer P.F., D'Angelo S.V., Mazzola G., Oestereich C., Barthels M., et al. Severe autoimmune protein S deficiency in a boy with idiopathic purpura fulminans. Br J Haematol 1995, 89:610-614.
126. Boccara O., Lesage F., Regnault V., Lasne D., Dupic L., Bourdon-Lanoy E., et al. Nonbacterial purpura fulminans and severe autoimmune acquired protein S deficiency associated with human herpesvirus-6 active replication. Br J Dermatol 2009, 161:181-183.
127. Levin M., Eley B.S., Louis J., Cohen H., Young L., Heyderman R.S. Postinfectious purpura fulminans caused by an autoantibody directed against protein S. J Pediatr 1995, 127:355-363.
128. Stahl C.P., Wideman C.S., Spira T.J., Haff E.C., Hixon G.J., Evatt B.L. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993, 81:1801-1807.
129. van Ommen C.H., van Wijnen M., de Groot F.G., van der Horst C.M., Peters M. Postvaricella purpura fulminans caused by acquired protein s deficiency resulting from antiprotein s antibodies: search for the epitopes. J Pediatr Hematol Oncol 2002, 24:413-416.
130. Molino D., De Lucia D., Marotta R., Perna A., Lombardi C., Cirillo M., et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int 2005, 68:1223-1229.
131. Torricelli M., Sabatini L., Florio P., Scaccia V., Voltolini C., Biliotti G., et al. Levels of antibodies against protein C and protein S in pregnancy and in preeclampsia. J Matern Fetal Neonatal Med 2009, 22:993-999.
132. Bartunek J., Barbato E., Vercruysse K., Duby C., Wijns W., Heyndrickx G., et al. Safety and Efficacy of Anti-von Willebrand Factor Nanobody® ALX-0081 in Stable Angina Patients Undergoing Percutaneous Coronary Intervention. Circulation 2010, 122:A15084.